DATOPOTAMAB DERUXTECAN

Information current as at: 1 July 2026

PBAC meeting date: November 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Datroway®
Form and strength:
  • Solution concentrate for I.V. infusion 100 mg in 5 mL
Submission sponsor:
ASTRAZENECA PTY LTD
Condition/indication:
(therapeutic use)
  • Breast cancer
Listing requested:
To request listing of datopotamab deruxtecan for the first-line treatment of patients with unresectable or metastatic triple-negative breast cancer who are not candidates for programmed death ligand-1 [PD-(L)1] inhibitor therapy.
Funding program:
PBS Section 100 (Efficient Funding of Chemotherapy)
Request authority level:
Authority Required (STREAMLINED)
PBAC Submission type:
New PBS listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2026 PBAC meeting
2Opportunity for consumer comment:
Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a1271
Page last updated
23 July 2026
Return to the Medicine Status Listing
v.9.19